Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The therapeutic potential of κ-opioids for treatment of pain and addiction.

× No keyword cloud information.

7 in total

1. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors: Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal: Proc Natl Acad Sci U S A Date: 2010-06-03 Impact factor: 11.205

Review 2. Kappa-opioid receptors and analgesia.

Authors: M J Millan
Journal: Trends Pharmacol Sci Date: 1990-02 Impact factor: 14.819

Review 3. Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Authors: Michael R Bruchas; Charles Chavkin
Journal: Psychopharmacology (Berl) Date: 2010-04-17 Impact factor: 4.530

4. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Authors: Stephen D Mague; Andrea M Pliakas; Mark S Todtenkopf; Hilarie C Tomasiewicz; Yan Zhang; William C Stevens; Robert M Jones; Philip S Portoghese; William A Carlezon
Journal: J Pharmacol Exp Ther Date: 2003-04 Impact factor: 4.030

5. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.

Authors: Jay P McLaughlin; Monica Marton-Popovici; Charles Chavkin
Journal: J Neurosci Date: 2003-07-02 Impact factor: 6.167

6. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.

Authors: Michael R Bruchas; Tao Yang; Selena Schreiber; Mia Defino; Steven C Kwan; Shuang Li; Charles Chavkin
Journal: J Biol Chem Date: 2007-08-16 Impact factor: 5.157

7. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.

Authors: Benjamin B Land; Michael R Bruchas; Julia C Lemos; Mei Xu; Erica J Melief; Charles Chavkin
Journal: J Neurosci Date: 2008-01-09 Impact factor: 6.167

7 in total

59 in total

1. Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.

Authors: Yan Zhou; Rachel Saylor Crowley; Konrad Ben; Thomas E Prisinzano; Mary Jeanne Kreek
Journal: Brain Res Date: 2017-03-02 Impact factor: 3.252

2. 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors: Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal: J Biol Chem Date: 2012-06-26 Impact factor: 5.157

3. Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors: Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal: Am J Addict Date: 2015-12-21

4. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.

Authors: Selena S Schattauer; Jamie R Kuhar; Allisa Song; Charles Chavkin
Journal: Cell Signal Date: 2017-01-11 Impact factor: 4.315

Review 5. Allostery at opioid receptors: modulation with small molecule ligands.

Authors: Kathryn E Livingston; John R Traynor
Journal: Br J Pharmacol Date: 2017-06-07 Impact factor: 8.739

Review 6. A Review of the Neurobiological Basis of Trauma-Related Dissociation and Its Relation to Cannabinoid- and Opioid-Mediated Stress Response: a Transdiagnostic, Translational Approach.

Authors: Ruth A Lanius; Jenna E Boyd; Margaret C McKinnon; Andrew A Nicholson; Paul Frewen; Eric Vermetten; Rakesh Jetly; David Spiegel
Journal: Curr Psychiatry Rep Date: 2018-11-07 Impact factor: 5.285

The therapeutic potential of κ-opioids for treatment of pain and addiction.